Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDA...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research : BCR Vol. 26; no. 1; p. 35
Main Authors Smoots, Stephen G, Schreiber, Anna R, Jackson, Marilyn M, Bagby, Stacey M, Dominguez, Adrian T A, Dus, Evan D, Binns, Cameron A, MacBeth, Morgan, Whitty, Phaedra A, Diamond, Jennifer R, Pitts, Todd M
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 01.03.2024
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence. TNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated β-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment. OKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro. The addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC.
AbstractList Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence. TNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated β-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment. OKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro. The addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC.
BACKGROUNDTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence.METHODSTNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated β-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment.RESULTSOKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro.CONCLUSIONThe addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC.
Abstract Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence. Methods TNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated β-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment. Results OKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro. Conclusion The addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence. TNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated [beta]-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment. OKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro. The addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC.
Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence. Methods TNBC cell lines were treated with doxorubicin and CellTiter-Glo was used to assess proliferation and determine doxorubicin sensitivity. Select cell lines were treated with OKI-005 (in vitro version of bocodepsin) and doxorubicin and assessed for proliferation, apoptosis as measured by Annexin V/PI, and cell cycle by flow cytometry. Immunoblotting was used to assess changes in mediators of apoptosis, cell cycle arrest, and senescence. Senescence was measured by the senescence-associated [beta]-galactosidase assay. An MDA-MB-231 xenograft in vivo model was treated with bocodepsin, doxorubicin, or the combination and assessed for inhibition of tumor growth. shRNA knockdown of p53 was performed in the CAL-51 cell line and proliferation, apoptosis and senescence were assessed in response to combination treatment. Results OKI-005 and doxorubicin resulted in synergistic antiproliferative activity in TNBC cells lines regardless of p53 mutation status. The combination led to increased apoptosis and decreased senescence. In vivo, the combination resulted in increased tumor growth inhibition compared to either single agent. shRNA knock-down of p53 led to increased doxorubicin-induced senescence that was decreased with the addition of OKI-005 in vitro. Conclusion The addition of bocodepsin to doxorubicin resulted in synergistic antiproliferative activity in vitro, improved tumor growth inhibition in vivo, and promotion of apoptosis which makes this a promising combination to overcome doxorubicin resistance in TNBC. Bocodepsin is currently in clinical development and has a favorable toxicity profile compared to other HDAC inhibitors supporting the feasibility of evaluating this combination in patients with TNBC. Keywords: Triple-negative breast cancer, Doxorubicin, Histone deacetylase inhibitor
ArticleNumber 35
Audience Academic
Author Bagby, Stacey M
Jackson, Marilyn M
Pitts, Todd M
Smoots, Stephen G
Whitty, Phaedra A
Dominguez, Adrian T A
Dus, Evan D
Schreiber, Anna R
Binns, Cameron A
MacBeth, Morgan
Diamond, Jennifer R
Author_xml – sequence: 1
  givenname: Stephen G
  surname: Smoots
  fullname: Smoots, Stephen G
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 2
  givenname: Anna R
  surname: Schreiber
  fullname: Schreiber, Anna R
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 3
  givenname: Marilyn M
  surname: Jackson
  fullname: Jackson, Marilyn M
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 4
  givenname: Stacey M
  surname: Bagby
  fullname: Bagby, Stacey M
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 5
  givenname: Adrian T A
  surname: Dominguez
  fullname: Dominguez, Adrian T A
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 6
  givenname: Evan D
  surname: Dus
  fullname: Dus, Evan D
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 7
  givenname: Cameron A
  surname: Binns
  fullname: Binns, Cameron A
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 8
  givenname: Morgan
  surname: MacBeth
  fullname: MacBeth, Morgan
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 9
  givenname: Phaedra A
  surname: Whitty
  fullname: Whitty, Phaedra A
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 10
  givenname: Jennifer R
  surname: Diamond
  fullname: Diamond, Jennifer R
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA
– sequence: 11
  givenname: Todd M
  surname: Pitts
  fullname: Pitts, Todd M
  email: todd.pitts@cuanschutz.edu
  organization: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA. todd.pitts@cuanschutz.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38429789$$D View this record in MEDLINE/PubMed
BookMark eNptkstu1DAUhiNURC_wAiyQJTZs0jrxJfZyNFw6otJsQGJnnTgnU4-SONhOBQ_C--LplKog5IXt4-__j4_0nxcnk5-wKF5X9LKqlLyKFaNClbTmJa0arUvxrDiruBSl4PW3kyfn0-I8xj3NlBLqRXHKFK91o_RZ8Wt7h8H60U070vkfPiyts24iAaOLCSaLJN9ScPOA5YQ7SO4OSRsQYiL28B7IEg_qdIvEDhAj2ZQJwg7ToXr9frXODreudckH0nrrO5yz4Gr7eVPmX5PkyRz86BMSmP2cfG78snjewxDx1cN-UXz9-OHL-rq82X7arFc3peVCpxKaGutKVthzy7vGtlYpSxnUoACk4mBrIaDBtmMVZa3QSguUtu4415mn7KLYHH07D3szBzdC-Gk8OHNf8GFnICRnBzSoFZMVbRvUlItGAGOUN7a30Iiecshe745eeZrvC8ZkRhctDgNM6Jdoas14LTVnKqNv_0H3fglTnjRTQirJJX1C7SD3d1PvUwB7MDWrRvFGMq1kpi7_Q-XV4ehsDkzvcv0vQX0U2OBjDNg_zl1Rc8iVOebK5FyZ-1wZkUVvHn68tCN2j5I_QWK_ATK8ygg
Cites_doi 10.3390/cancers13040713
10.3390/ijms20071601
10.1016/j.bbacli.2015.03.003
10.3389/fimmu.2021.607282
10.1186/s13058-020-01296-5
10.1042/CBI20120274
10.1016/j.ccr.2012.04.027
10.1158/1535-7163.MCT-17-0146
10.1158/1535-7163.MCT-21-0455
10.12659/MSM.914295
10.18632/oncotarget.5232
10.1016/j.gpb.2022.01.004
10.1016/j.semcdb.2017.08.004
10.1038/nature11412
10.3390/ph16050672
10.3389/fimmu.2023.1164514
10.1158/2159-8290.CD-18-0879
10.1016/S1470-2045(17)30180-8
10.1007/s12282-020-01086-z
10.1056/NEJMoa2112651
10.1158/2326-6066.CIR-18-0875
10.1101/gad.235184.113
10.1158/1078-0432.CCR-14-0821
10.3390/cells8121501
10.1038/cdd.2017.180
10.7150/thno.60503
10.1016/j.molcel.2012.01.020
10.18632/oncotarget.13475
10.1101/gad.212282.112
10.1007/s10637-010-9596-y
10.1007/s10549-022-06801-2
10.1111/cas.14116
10.1158/1535-7163.MCT-14-0538-T
10.1371/journal.pone.0238856
10.1038/sj.onc.1209202
10.1073/pnas.1002298107
10.3389/fcell.2021.645593
10.1101/gad.17276711
10.1200/PO.17.00245
10.3389/fmolb.2022.836417
10.3389/fimmu.2023.1260545
10.1016/j.mad.2022.111689
10.1016/j.yexcr.2004.01.017
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID NPM
AAYXX
CITATION
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
7X8
DOA
DOI 10.1186/s13058-024-01799-5
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Publicly Available Content Database


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1465-542X
EndPage 35
ExternalDocumentID oai_doaj_org_article_e983610b7e904575a33047cfca75f04a
A784763986
10_1186_s13058_024_01799_5
38429789
Genre Journal Article
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: NIH HHS
  grantid: 5P30CA046934-25
GroupedDBID ---
04C
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABUWG
ACGFO
ACGFS
ACJQM
ACMJI
ACPRK
ACRMQ
ADBBV
ADFRT
ADINQ
ADUKV
AENEX
AFKRA
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BMSDO
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
DU5
E3Z
EBD
EBLON
EBS
EIHBH
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
ICW
IHR
INH
INR
ITC
KQ8
LGEZI
LOTEE
NADUK
NPM
NXXTH
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
U2A
UKHRP
WOQ
AAYXX
CITATION
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
7X8
ID FETCH-LOGICAL-c459t-a72e2161ef4c4d7cbc88c03a2a8aa684ac255a7ebd3103b59895e6c2d4494d703
IEDL.DBID 7X7
ISSN 1465-542X
1465-5411
IngestDate Tue Oct 22 15:13:30 EDT 2024
Fri Oct 25 23:23:55 EDT 2024
Mon Nov 18 14:34:33 EST 2024
Tue Nov 19 21:37:46 EST 2024
Tue Nov 12 23:46:02 EST 2024
Thu Nov 21 23:22:57 EST 2024
Sat Nov 02 12:21:32 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Doxorubicin
Histone deacetylase inhibitor
Triple-negative breast cancer
Language English
License 2024. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-a72e2161ef4c4d7cbc88c03a2a8aa684ac255a7ebd3103b59895e6c2d4494d703
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.proquest.com/docview/2956864608?pq-origsite=%requestingapplication%
PMID 38429789
PQID 2956864608
PQPubID 2034567
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_e983610b7e904575a33047cfca75f04a
proquest_miscellaneous_2934269438
proquest_journals_2956864608
gale_infotracmisc_A784763986
gale_infotracacademiconefile_A784763986
crossref_primary_10_1186_s13058_024_01799_5
pubmed_primary_38429789
PublicationCentury 2000
PublicationDate 2024-03-01
PublicationDateYYYYMMDD 2024-03-01
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Breast cancer research : BCR
PublicationTitleAlternate Breast Cancer Res
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AI Aljohani (1799_CR32) 2023; 198
ZN Demidenko (1799_CR39) 2010; 107
J Munro (1799_CR40) 2004; 295
R Salama (1799_CR37) 2014; 28
E Bientinesi (1799_CR9) 2022; 206
M Li (1799_CR29) 2012; 46
Y Lu (1799_CR33) 2020; 27
1799_CR2
JR Diamond (1799_CR21) 2022; 21
1799_CR7
T Inao (1799_CR8) 2019; 110
O Castellanet (1799_CR27) 2021; 11
F Yang (1799_CR5) 2014; 1845
B Lian (1799_CR28) 2023; 14
Cancer Genome Atlas N (1799_CR15) 2012; 490
D Capece (1799_CR12) 2018; 78
1799_CR22
N Holay (1799_CR45) 2023; 14
M Dickinson (1799_CR20) 2010; 28
O Maertens (1799_CR41) 2019; 9
1799_CR26
RNDH Amaria (1799_CR44) 2023
X Hu (1799_CR6) 2019; 25
C Tonelli (1799_CR31) 2015; 6
D Kenzelmann Broz (1799_CR30) 2013; 27
J Yuan (1799_CR34) 2006; 25
JG Jackson (1799_CR38) 2012; 21
R Kumari (1799_CR10) 2021; 9
NM Almansour (1799_CR1) 2022; 9
EH Baugh (1799_CR16) 2018; 25
1799_CR19
TR Mancilla (1799_CR18) 2020; 15
1799_CR36
T Yamada (1799_CR42) 2018; 17
JJ Tentler (1799_CR14) 2015; 14
P Schmid (1799_CR4) 2022; 386
KC Nitiss (1799_CR3) 2014; 20
R Dummer (1799_CR43) 2017; 18
S Zheng (1799_CR24) 2022; 20
JA Marin-Jimenez (1799_CR25) 2021; 12
EA O’Reilly (1799_CR11) 2015; 3
A Zuryn (1799_CR35) 2012; 36
Y Chien (1799_CR13) 2011; 25
K Hientz (1799_CR17) 2017; 8
X Wang (1799_CR23) 2019; 7
References_xml – ident: 1799_CR19
  doi: 10.3390/cancers13040713
– ident: 1799_CR22
  doi: 10.3390/ijms20071601
– volume: 3
  start-page: 257
  year: 2015
  ident: 1799_CR11
  publication-title: BBA Clin
  doi: 10.1016/j.bbacli.2015.03.003
  contributor:
    fullname: EA O’Reilly
– volume: 12
  start-page: 607282
  year: 2021
  ident: 1799_CR25
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.607282
  contributor:
    fullname: JA Marin-Jimenez
– ident: 1799_CR2
  doi: 10.1186/s13058-020-01296-5
– volume: 36
  start-page: 1129
  issue: 12
  year: 2012
  ident: 1799_CR35
  publication-title: Cell Biol Int
  doi: 10.1042/CBI20120274
  contributor:
    fullname: A Zuryn
– volume: 21
  start-page: 793
  issue: 6
  year: 2012
  ident: 1799_CR38
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.04.027
  contributor:
    fullname: JG Jackson
– volume: 17
  start-page: 17
  issue: 1
  year: 2018
  ident: 1799_CR42
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-17-0146
  contributor:
    fullname: T Yamada
– volume-title: Novel strategy for RAS-Pathway Targeting: initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with Binimetinibin patients with RAS-Pathway-mutated solid tumors and NRAS-Mutated Melanoma
  year: 2023
  ident: 1799_CR44
  contributor:
    fullname: RNDH Amaria
– volume: 21
  start-page: 397
  issue: 3
  year: 2022
  ident: 1799_CR21
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-21-0455
  contributor:
    fullname: JR Diamond
– volume: 25
  start-page: 3617
  year: 2019
  ident: 1799_CR6
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.914295
  contributor:
    fullname: X Hu
– volume: 6
  start-page: 24611
  issue: 28
  year: 2015
  ident: 1799_CR31
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5232
  contributor:
    fullname: C Tonelli
– volume: 20
  start-page: 587
  issue: 3
  year: 2022
  ident: 1799_CR24
  publication-title: Genomics Proteom Bioinf
  doi: 10.1016/j.gpb.2022.01.004
  contributor:
    fullname: S Zheng
– volume: 78
  start-page: 51
  year: 2018
  ident: 1799_CR12
  publication-title: Semin Cell Dev Biol
  doi: 10.1016/j.semcdb.2017.08.004
  contributor:
    fullname: D Capece
– volume: 490
  start-page: 61
  issue: 7418
  year: 2012
  ident: 1799_CR15
  publication-title: Nature
  doi: 10.1038/nature11412
  contributor:
    fullname: Cancer Genome Atlas N
– ident: 1799_CR36
  doi: 10.3390/ph16050672
– volume: 14
  start-page: 1164514
  year: 2023
  ident: 1799_CR28
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1164514
  contributor:
    fullname: B Lian
– volume: 9
  start-page: 526
  issue: 4
  year: 2019
  ident: 1799_CR41
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0879
  contributor:
    fullname: O Maertens
– volume: 18
  start-page: 435
  issue: 4
  year: 2017
  ident: 1799_CR43
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30180-8
  contributor:
    fullname: R Dummer
– volume: 27
  start-page: 903
  issue: 5
  year: 2020
  ident: 1799_CR33
  publication-title: Breast Cancer
  doi: 10.1007/s12282-020-01086-z
  contributor:
    fullname: Y Lu
– volume: 386
  start-page: 556
  issue: 6
  year: 2022
  ident: 1799_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2112651
  contributor:
    fullname: P Schmid
– volume: 7
  start-page: 1318
  issue: 8
  year: 2019
  ident: 1799_CR23
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-18-0875
  contributor:
    fullname: X Wang
– volume: 28
  start-page: 99
  issue: 2
  year: 2014
  ident: 1799_CR37
  publication-title: Genes Dev
  doi: 10.1101/gad.235184.113
  contributor:
    fullname: R Salama
– volume: 20
  start-page: 4737
  issue: 18
  year: 2014
  ident: 1799_CR3
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-0821
  contributor:
    fullname: KC Nitiss
– ident: 1799_CR7
  doi: 10.3390/cells8121501
– volume: 25
  start-page: 154
  issue: 1
  year: 2018
  ident: 1799_CR16
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2017.180
  contributor:
    fullname: EH Baugh
– volume: 11
  start-page: 9180
  issue: 19
  year: 2021
  ident: 1799_CR27
  publication-title: Theranostics
  doi: 10.7150/thno.60503
  contributor:
    fullname: O Castellanet
– volume: 1845
  start-page: 84
  issue: 1
  year: 2014
  ident: 1799_CR5
  publication-title: Biochim Biophys Acta
  contributor:
    fullname: F Yang
– volume: 46
  start-page: 30
  issue: 1
  year: 2012
  ident: 1799_CR29
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2012.01.020
  contributor:
    fullname: M Li
– volume: 8
  start-page: 8921
  issue: 5
  year: 2017
  ident: 1799_CR17
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13475
  contributor:
    fullname: K Hientz
– volume: 27
  start-page: 1016
  issue: 9
  year: 2013
  ident: 1799_CR30
  publication-title: Genes Dev
  doi: 10.1101/gad.212282.112
  contributor:
    fullname: D Kenzelmann Broz
– volume: 28
  start-page: 3
  issue: Suppl 1
  year: 2010
  ident: 1799_CR20
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-010-9596-y
  contributor:
    fullname: M Dickinson
– volume: 198
  start-page: 423
  issue: 3
  year: 2023
  ident: 1799_CR32
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-022-06801-2
  contributor:
    fullname: AI Aljohani
– volume: 110
  start-page: 2690
  issue: 9
  year: 2019
  ident: 1799_CR8
  publication-title: Cancer Sci
  doi: 10.1111/cas.14116
  contributor:
    fullname: T Inao
– volume: 14
  start-page: 1117
  issue: 5
  year: 2015
  ident: 1799_CR14
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-14-0538-T
  contributor:
    fullname: JJ Tentler
– volume: 15
  start-page: e0238856
  issue: 9
  year: 2020
  ident: 1799_CR18
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0238856
  contributor:
    fullname: TR Mancilla
– volume: 25
  start-page: 1753
  issue: 12
  year: 2006
  ident: 1799_CR34
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209202
  contributor:
    fullname: J Yuan
– volume: 107
  start-page: 9660
  issue: 21
  year: 2010
  ident: 1799_CR39
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1002298107
  contributor:
    fullname: ZN Demidenko
– volume: 9
  start-page: 645593
  year: 2021
  ident: 1799_CR10
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2021.645593
  contributor:
    fullname: R Kumari
– volume: 25
  start-page: 2125
  issue: 20
  year: 2011
  ident: 1799_CR13
  publication-title: Genes Dev
  doi: 10.1101/gad.17276711
  contributor:
    fullname: Y Chien
– ident: 1799_CR26
  doi: 10.1200/PO.17.00245
– volume: 9
  start-page: 836417
  year: 2022
  ident: 1799_CR1
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2022.836417
  contributor:
    fullname: NM Almansour
– volume: 14
  start-page: 1260545
  year: 2023
  ident: 1799_CR45
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1260545
  contributor:
    fullname: N Holay
– volume: 206
  start-page: 111689
  year: 2022
  ident: 1799_CR9
  publication-title: Mech Ageing Dev
  doi: 10.1016/j.mad.2022.111689
  contributor:
    fullname: E Bientinesi
– volume: 295
  start-page: 525
  issue: 2
  year: 2004
  ident: 1799_CR40
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2004.01.017
  contributor:
    fullname: J Munro
SSID ssj0017858
Score 2.496386
Snippet Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC,...
Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy...
BackgroundTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy...
BACKGROUNDTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy...
Abstract Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative...
SourceID doaj
proquest
gale
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 35
SubjectTerms Annexin V
Apoptosis
Autophagy
Bioavailability
Biotechnology industry
Breast cancer
Cancer
Cancer therapies
Cell cycle
Cell division
Cell fate
Chemoresistance
Chemotherapy
DNA damage
DNA repair
Doxorubicin
Flow cytometry
Genes
Growth inhibition
Histone deacetylase
Histone deacetylase inhibitor
Immunoblotting
Kinases
Mutation
Prognosis
Proteins
Senescence
Toxicity
Triple-negative breast cancer
Tumor proteins
Tumors
β-Galactosidase
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLgpZHoCAjITgga5fEj_FxKVRbUOmFSr1ZtuMtPZBEaVZqfwj_lxknu2LhwIVjYuf5ffZ8k8yMGXsdgknKBCkqW0eBFq8UVtYgTIoWap1W8j0lCp9-1ctz-flCXfy21BfFhI3lgccXN0sWKjTxeEqL6sMoTw64iavojVrN5SiN5uXGmZr-HxhQsEmRAT27xplagUB7JIiBVqgdM5Sr9f89J_-hNLPFOX7A7k9SkS_GW3zI7qRmnx0sGnSTf9zyNzwHb-av4vvs7un0j_yA_TxDdiKP0Cbxur1p-3WgFo5-NWlFBJnj1tDTF3bRpMtc-ZsHCk4feKT2nlM0_CVHbcgjqWt-IsaIcdq7_Lg4wjN8vwo4GfQ8tJQV3-EBs7MvJ1SHlA8t73KUX-K-a7uhxQs_YufHn74dLcW0-IKIUtlBeFOmEuUgohVlbWKIAHFe-dKD9xqkj-iMeJNCTSuVBWXBqqRjWUuJYOM88pjtNW2TnjIewJOnR4VeKonuZ4hSr2oTSqQDbtmCvdtg4bqxxobLvgloNyLnEDmXkXOqYB8Irm1Pqo-ddyBr3MQa9y_WFOwtge1oFA-9j35KRsAbpnpYbmHQaqN4A12ww52eOPribvOGLm4a_deupBxMLfUcCvZq20xHUkRbk9o19alyFnGFfZ6MNNs-UgWoEgzYZ__jUZ-ze2UmPsXNHbK9oV-nFyikhvAyj5lf5YEY0g
  priority: 102
  providerName: Directory of Open Access Journals
Title Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
URI https://www.ncbi.nlm.nih.gov/pubmed/38429789
https://www.proquest.com/docview/2956864608
https://search.proquest.com/docview/2934269438
https://doaj.org/article/e983610b7e904575a33047cfca75f04a
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgkxAvE2z8CIzKSAgekNU2sWP7CbVjUwfahiYmVbxYtuMWHkiyNJXgD-H_5c5JiwoSL5USO0mj73z33eXuTMgr52QQ0nGW6cIzsHgp07xQTAavVZGHBR9jofDFZT674R_mYt4H3FZ9WuVGJ0ZFXVQeY-TDFOvacp6P1Lv6luGuUfh1td9C4y7ZH6dgykGe5XzrcOHG86qrLhJM8PF4UzSj8uEKdLdQDCwUQ5nUTOwYpti__18t_Rf3jDbo7AE56MkjnXRoPyR3QnlIjiYlOM7ff9LXNKZzxjj5Ibl30X81PyK_rkBe4S3BStGi-lE1a4cjFDxtZI8AO4WjtsGYOyvDMvYCpw7T1VvqcbyhmB-_pMAWqUe-Tc9Zl0OOZ2fvJydwh6_fHKiHhroK6-RruGB49fEcO5PStqJ1zPsL1NZV3Vbw4Efk5uz088mM9dsxMM-FbpmVaUiBIAJ-nhfSO6-UH2U2tcraXHHrwT2xMrgC9y5zQistQu7TgnOAHzTLY7JXVmV4SqhTFn0_bP2ScXBInef5opAuBQGBI52QtxssTN113TDRW1G56ZAzgJyJyBmRkCnCtZ2JHbPjiapZmn4BmqBVBlQRRFMDi5XCYiBH-oW3UixG3CbkDYJtcF23jfW2L0-AP4wdssxEgh0HOqfyhBzvzIT16HeHN-Jien2wMn-kNyEvt8N4Jea4laFa45ws1hVnMOdJJ2bbV8oU8Aap9LP_3_w5uZ9GkcYcuWOy1zbr8AJIU-sGcWUMyP709PLT9SCGHuD3evrlN7CpFoc
link.rule.ids 314,780,784,864,2102,12056,21388,27924,27925,31719,31720,33744,33745,43310,43805
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegk4AXBBuMwAAjIXhAVtvEju0n1I1NLVs7hDZpb5btuIUHkpCmEvwh_L_cuWlRQeIxsfNh3fnud-f7IOS1czII6TjLdOEZaLyUaV4oJoPXqsjDnA8xUXg6y8fX_OONuOkcbssurHIjE6OgLiqPPvJ-inltOc8H6n39nWHXKDxd7Vpo3CZ7WDld9Mje8ens0-ftOYJUsUMniAPBBB8ON2kzKu8vQXoLxUBHMeRKzcSOaooV_P-V03-hz6iFzh6Q-x18pKM1vR-SW6HcJwejEkznbz_pGxoDOqOnfJ_cmXbn5gfk1yVwLKwT9BQtqh9Vs3I4QsHWRvwIhKdw1TbodWdlWMRq4NRhwHpLPY43FCPkFxTwIvWIuOmEraPI8e74w-gE3vDlqwMB0VBXYaZ8DQ_0L88nWJuUthWtY-RfoLau6raCDz8i12enVydj1jVkYJ4L3TIr05ACRAQKel5I77xSfpDZ1Cprc8WtBwPFyuAK7F7mhFZahNynBefAACBbHpNeWZXhCaFOWbT-sPhLxsEkdZ7n80K6FFgErnRC3m1oYep13Q0T7RWVmzXlDFDORMoZkZBjJNd2JtbMjjeqZmG6LWiCVhmARWBODThWCouuHOnn3koxH3CbkLdIbIM7u22st12CAvww1sgyIwmaHACdyhNytDMTdqTfHd6wi-kkwtL84d-EvNoO45MY5VaGaoVzsphZnMGcwzWbbZeUKUAOUumn_3_5S3J3fDW9MBeT2fkzci-N7I0Rc0ek1zar8BwgVOtedPvkN9i4Fz8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overcoming+doxorubicin+resistance+in+triple-negative+breast+cancer+using+the+class+I-targeting+HDAC+inhibitor+bocodepsin%2FOKI-179+to+promote+apoptosis&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Smoots%2C+Stephen+G&rft.au=Schreiber%2C+Anna+R&rft.au=Jackson%2C+Marilyn+M&rft.au=Bagby%2C+Stacey+M&rft.date=2024-03-01&rft.eissn=1465-542X&rft.volume=26&rft.issue=1&rft.spage=35&rft.epage=35&rft_id=info:doi/10.1186%2Fs13058-024-01799-5&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon